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Background: Host-range restricted poxviruses make promising vaccine vectors due to their safety profile and
immunogenicity. An understanding of the host innate immune responses produced by different poxvirus vectors
would aid in the assessment, selection and rational design of improved vaccines for human and veterinary
applications. Novel avipoxviruses are being assessed to determine if they are different from other poxvirus vectors.
Analysis of the transcriptome induced in a mouse model would aid in determining if there were significant
differences between different poxvirus vectors which may reflect different adjuvant potential as well as establish if
they should be further evaluated as vaccine vectors.
Results: We compared host transcript abundance in the spleens of BALB/c mice twenty four hours after
intravenous infection (105 pfu/mouse) with six host-restricted poxvirus species from three genera, namely Lumpy
Skin Disease virus (LSDV), Canarypox virus (CNPV), Fowlpox virus (FWPV), modified vaccinia Ankara (MVA) and two
novel South African avipoxviruses, Feral Pigeonpox virus (FeP2) and Penguinpox virus (PEPV). These six viruses
produced qualitatively and quantitatively distinct host responses with LSDV, followed by MVA, inducing the
greatest interferon (IFN) response. FeP2 and PEPV caused very little change to host transcript abundance compared to
the other 4 viruses tested. CNPV and FWPV induced the up regulation of two immunoglobulin genes (Ighg and Ighg3
(IgG3)) with CNPV inducing a third, Ighm (IgM). HIV-1–specific IgG3 antibodies have been correlated with decreased risk
of HIV-1 infection in the RV144 trial, which included a CNPV-based vector (Yates et al. (Sci Transl Med, 6(228) p228,
2014). Up regulation of IgG3 by CNPV and FWPV but not the other poxviruses tested in vivo, implies that these two
avipoxvirus-vector backbones may be involved in stimulation of the clinically important IgG3 antibody subclass.
Differential transcript abundance associated with the different poxviruses is further discussed with particular
emphasis on responses related to immune responses.
Conclusion: Six, genetically diverse host-restricted poxviruses produce different responses in a mouse model
early after infection. These differences may affect the immune response induced to vaccine antigen in vectors
based on these viruses. The two novel avipoxviruses were clearly distinguishable from the other viruses.
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Although a number of different poxvirus-based vaccine
vectors are available [1–7], there is still a need for add-
itional vaccine vectors as well as improvement of the vec-
tors. The unique response elicited by the host to different
vectors means that vectors can be selected or engineered
according to a desired host response. Host-range restricted
poxviruses have been shown to successfully activate the
host immune system [8, 9] and evidence exists that each
virus does this in a different way, with an accompanying
different pattern of transcript abundance [10–15]. The pox-
viruses ALVAC (based on canarypox virus), modified vac-
cinia Ankara (MVA) and NYVAC (both based on vaccinia
virus (VACV) and have specific deletions) produce distinct
innate immune profiles, characterised by different induc-
tion of pro-inflammatory and antiviral cytokines and che-
mokines in both rhesus monkeys and human PBMC [16].
It has been shown that in non-permissive cells, Fowlpox
virus (FWPV) proceeds further into the poxvirus life cycle
than Canarypox virus (CNPV) [17]. Heterologous HIV
gag/pol and env genes are more efficiently expressed by
FWPV than CNPV in vitro due to longer transgene ex-
pression [18]. However, the only successful HIV-1 vaccine
clinical trial to date (31.2 % protection from HIV-1 infec-
tion) has been the Thai RV144 trial involving priming
with ALVAC expressing HIV-1 gp120/Gag-Pro and
boosting with a recombinant glycoprotein 120 subunit,
AIDSVAX [7]. Head to head comparisons of poxvirus-
vectored vaccines would help to establish the differences
between the different vaccine vectors and the vaccine-
induced response to achieve protection against pathogens
and cancers.
Innate immunity is critical for directing the adaptive
immune response to antigen and influences the magni-
tude and quality of the long-lived, protective immune re-
sponses to pathogens or vaccines [19]. Application of
the systems biology approach to vaccine development
(“systems vaccinology”) and establishment of innate im-
mune signatures has proven useful in predicting the im-
munogenicity of the highly effective yellow fever vaccine
(YF-17D) [20], seasonal influenza vaccines [21] and the
immunogenic but inefficacious Merck Adenovirus type 5
(Ad5) based HIV vaccine [22]. A better understanding of
the mechanisms underlying the optimal innate immune
responses would aid rational vaccine development.
Type 1 interferons (IFNα/β) are expressed rapidly in
response to viral infection, and, in turn activate many
interferon stimulated genes (ISGs) which exert various
antiviral effector functions. A fine balance of IFN is re-
quired for successful vaccination using a live virus vec-
tor. The vector should induce enough type I IFNs to
activate the immune system, yet not enough to inhibit
viral DNA replication and gene expression before anti-
gen presentation can occur [23]. This is corroborated byJohnson et al. (2012), who compared recombinant (r) Ad
types 5, 28 and 35. Specific IFN-α induction by rAd28
and rAd35 significantly lowered the immunogenicity of
these vectors compared to rAd5 which did not induce
IFN-α expression [24]. The effect of type 1 IFN responses
on different vaccines requires delineation of innate im-
mune signatures and how they determine subsequent
adaptive responses.
Microarray analyses performed in vitro have been used
to investigate the effects of VACV ([12], MVA [11] and
NYVAC [13] infection on HeLa cell gene expression.
Gene expression profiles in human monocyte derived
dendritic cells (MDDCs) have also been generated with
MVA, NYVAC [14] and ALVAC [15]. Furthermore, a
comparison of the closely related VACV-derived vectors
NYVAC and MVA revealed significant differences in anti-
gen production and host gene dysregulation in cell culture
[25]. Consequently we hypothesized that genetically di-
verse poxvirus strains would induce significant differences
in host gene expression. The interaction of poxviruses
with the host is not just dependent on the actual cell in-
fected by the virus but also on the factors secreted by
those infected cells and their effects on the surrounding
cells. Although in vitro expression studies have provided
useful information, gene expression profiles performed in
cell culture may not accurately reflect the changes in the
system that occurs as a result of infection in vivo. A recent
study in Rhesus Macaques showed that ALVAC induced
distinct cytokine and chemokine levels compared to the
vaccinia virus-based vectors MVA and NYVAC and that
multiple subsets of peripheral blood mononuclear cells
(PBMC) are likely to contribute to the overall response to
different poxviruses [16].
In this study we compared the effects of the capri-
poxvirus, lumpy skin disease virus (LSDV), the orthopox-
virus, MVA, and the avipoxviruses, CNPV, FWPV, a novel
pigeonpox virus (FeP2) [26, 27] and a novel penguinpox
virus (PEPV) [27–29] on host gene expression profiles in
the spleens of BALB/c mice. None of these viruses complete
their replication cycle in mice.
Results
Comparison of the host responses to different poxviruses
We compared the differential host gene expression in-
duced by six host-restricted poxviruses, MVA, LSDV,
FWPV, CNPV, FeP2 and PEPV, in the spleens of BALB/c
mice 24 h post infection. Transcripts with an adjusted p-
value < 0.05 were described as up-regulated if they had a
log2 fold change (FC) of ≥1, or down-regulated if they
had a log2FC of ≤ −1. A summary of the number of up
and down-regulated genes is given in Table 1. Full gene
lists are given in supplementary data (Additional file 1).
Quantitative RT-PCR showed all three housekeeping
genes (GAPDH, HPRT and CD51) to be expressed at
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Both IRF7 and Zbp1 were upregulated by all poxviruses
tested. IGFbp3 was shown to be downregulated by all
viruses. Overall the quantitative RT-PCR was more sensi-
tive than the microarray, but the trend observed in up-
and down-regulation of host gene expression was similar
for qRT-PCR and microarray analysis.
Unsupervised hierarchical clustering based on the genes
with p-value < 0.05 and log2FC above or below cutoff (>1,
<−1) showed that each virus induced a unique overall re-
sponse (Fig. 1). Venn diagrams highlight the number of
differences and similarities in the up- and down-regulated
genes between the viruses (Fig. 2). Fig. 2 a and b show the
differences in transcripts up (A) and (B) down-regulated
respectively between FWPV, CNPV, MVA and LSDV. The
Venn diagrams comparing FWPV, CNPV, MVA and
LSDV indicate that the majority of up-regulated genes are
shared amongst these 4 viruses (Fig. 2). The down-
regulated genes however, appear largely unique, especially
for LSDV and MVA (Fig. 2). FWPV and CNPV down
regulate a smaller number of genes in comparison to
LSDV and MVA. Comparison of avipoxvirus-induced up-
and down-regulated genes shows that FeP2 and PEPV in-
duce significantly less change in host transcript abundance
than FWPV and CNPV (Fig. 2). FeP2 induced the lowest
response (Fig. 2, Table 1). For all six viruses, more genes
were up-regulated than down-regulated (Table 1).
Histone transcripts
Previous studies have found that increased detection of
histone genes by poxvirus infection is described as an ex-
perimental artefact due to the de novo polyadenylation of
transcripts by the viral poly-A polymerase [30, 31]. Several
histone transcripts (39 in total) were down-regulated in
response to virus infection and, because any interpretation
of these transcripts would be speculative, these have been
excluded from further analysis.
Immunity and host defence response-related genes
Up-regulated immune response genes
Selected up-regulated genes involved in the immune re-
sponse are listed in Table 2. (Full list of up-regulated genes
is given in Additional file 1). Seventeen of these genes are
uniquely up-regulated by LSDV. RIG-I (Ddx58) senses
viral nucleic acid [32], Cebpb is important for macrophage
function [33] and control of inflammatory responses [34],
Tap1 and Tap2 genes are involved in antigen presen-
tation to MHC class 1 molecules [35], Ifitm3 and Ifi203
are interferon responsive genes (ISG), c-Myc and Mif are
transcription factors and Adar is an RNA editing enzyme.
There are eight genes induced by CNPV, FWPV and MVA,
which were not up-regulated in LSDV-infected mice. Two
of these include the cytidine deaminase, Apobec1, which
can edit viral nucleic acid and can thereby limit viralreplication [36], and Caspase 1 (Casp1), which is associated
with pyroptosis (Table 2).
Twenty six genes involved in the host immune/defence
response were up-regulated only in avipoxvirus-infected
mouse spleens (Table 2). The only avipoxvirus-specific gene
that was up-regulated by all four avipoxviruses was the
macrophage receptor with collagenous structure (Marco)
gene which has been shown to suppress early inflamma-
tory responses to virus infection [37]. There were, how-
ever, 9 additional genes which were up-regulated by both
CNPV and FWPV that were not induced by the other vi-
ruses. These included the chemokine Ccl6 which pro-
motes immune cell activation and recruitment [38] and
the immunoglobulin heavy chain genes, Ighg (IgG) and
Ighg3 (IgG3) (Table 2). Amongst these 26 avipoxvirus-
specific genes, 14 were exclusively up-regulated by FWPV.
The Nod-like receptor, NLR, Nod1, which has been shown
to be augmented in response to virus-induced production
of type I IFNs [39] was exclusively up-regulated by FWPV.
Four genes were uniquely up-regulated in CNPV-infected
mice including the immunoglobulin heavy chain gene,
Ighm (IgM), lymphocyte antigen 96 (Ly96), proteasome
maturation protein (Pomp) and Cathepsin L (Ctsl) (Table 2).
PePV and FeP2 induced very little immune activation ac-
cording to this microarray analysis.
Four genes were up-regulated by LSDV and MVA that
were not induced by the avipoxviruses in mice (Table 2),
namely the Moloney Leukemia Virus 10 (Mov10) gene,
hematopoietic SH2 domain containing protein (Hsh2d),
poly (ADP-ribose) polymerase family, member 11 (Parp11)
and schlafen 8 (Slfn8). No genes were uniquely up-
regulated in response to MVA infection (Table 2).
Down-regulated immune related genes
Selected down-regulated genes involved in the immune
response are listed in Table 3. Full lists of down-regulated
genes in response to each virus are given in Additional
file 1. MVA and LSDV induced the down regulation of
several genes that were not affected in avipoxvirus-infected
spleens. These included three forms of the chemokine
CCL21 (Ccl21a, Ccl21b, Ccl21c) which are potent che-
moattractants for lymphocytes and dendritic cells [40]
(Table 3). Furthermore, MVA and LSDV down regulate
the high affinity IgM and IgA FC receptor Fcamr. Fcamr is
the receptor for the FC fragment of immunoglobulins IgA
and IgM [41]. Interestingly, MVA, LSDV, FWPV and
CNPV all down regulate the gene encoding the murine
homolog for DC-specific ICAM-3–grabbing nonintegrin
(DC SIGN) (Cd209a), and MVA and LSDV down regu-
late an additional DC SIGN homolog, CD209b (SIGNR1)
(Table 3). LSDV uniquely down regulates CD59a, which is
the primary regulator of complement membrane attack in
mouse [42] and CD7 which is expressed on T- and NK
cells, and on cells in the early stages of T, B, and myeloid
Table 1 Summary of the number of significantly up- and
down-regulated transcripts with adjusted p-value < 0.05
Up-regulated Log2 FC > 1 Down-regulated Log2 FC < −1
MVA 299 (42NA) 177 (86NA)
LSDV 463 (111NA) 85 (11NA)
FWPV 433 (101NA) 62 (28NA)
CNPV 280 (31NA) 47 (11NA)
FeP2 20 (1NA) 3 (0NA)
PEPV 68 (6NA) 19 (2NA)
Genes are described as upregulated if they had a fold change of ≥2, or down-
regulated if they had a Log2 Fold change of ≤ −1. These included genes that
are not annotated and therefore do not have an Entrez ID. The number of
genes without annotation are indicated in brackets
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the immunoglobulin kappa chain complex (IgK) amongst
other immune related genes (Table 3). TLR11 is down-
regulated by MVA alone (Table 3).Type I interferon response
While many of the immunity related genes listed in
Table 2 are regulated in some way by Type I Interferons,
in order to characterise and compare the differences in
the Type I IFN-regulated responses between MVA, LSDV,
FWPV, CNPV, FeP2 and PEPV at 24 h, we analyzed a se-
lection of genes known to be involved in the IFN response
[44–46] (Fig. 3). This figure clearly shows that LSDVFig. 1 Heatmap comparing the differential expression induced in mouse s
skin disease virus (LSDV), modified vaccinia Ankara (MVA), canarypox virus (
with log2 fold change induction above or below the cutoff (±1) as compar
clustering of the samples is represented by dendograms. Clustering analysiinduces the greatest IFN response compared to the other
viruses (Fig. 3).
Caspases
MVA, FWPV and CNPV all up-regulated the protease cas-
pase 1 (casp1) whereas LSDV did not (Fig. 4). MVA, FWPV,
CNPV and LSDV significantly up-regulated caspase 4
(casp 4) (historically called caspase 11 in the mouse)
(Table 2). The SA avipoxviruses, FeP2 and PEPV did not
affect gene regulation of any caspase genes.
B- and T-cell specific responses
The up- and down-regulated genes involved in B cell
and T cell responses induced by the viruses in this study
were compared (Fig. 4). Fig. 4a highlights the regulated
genes that are involved in the T cell response. FeP2 and
PEPV regulated only one gene each involved in this re-
sponse, Ctla2a and major histocompatibility (MHC) class
I gene, H2-M2, respectively. The other four viruses differ-
entially regulated several MHC class I genes amongst
others (Fig. 4a). As highlighted in Table 2, the avipox-
viruses, CNPV and FWPV, exclusively up regulate im-
munoglobulin heavy chain genes, (Ighg (IgG) and Ighg3
(IgG3)) with CNPV inducing a third, Ighm (IgM) (Fig. 4b).
LSDV down regulates the immunoglobulin kappa (IgK)
chain complex (Fig. 4b). In addition to these, the poxvi-
ruses differentially regulate genes for FC receptors and
complement (Fig. 4b).pleens in response to pigeonpox (FeP2), penguinpox (PEPV), lumpy
CNPV) and fowlpox virus (FWPV). Only genes (with p-value < 0.05)
ed to the mock infected control are shown. Unsupervised hierarchical
s and heatmap was performed in the R package, gplots (Warnes, 2009)
Fig. 2 Venn diagrams showing the overlap between the differentially up-regulated (a) and down-regulated (b) transcripts induced by canarypox
virus (CNPV), fowlpox virus (FWPV), modified vaccinia Ankara (MVA) and lumpy skin disease virus (LSDV) and the up-regulated (c) and down-regulated
(d) transcripts induced by the four avipoxviruses. For each diagram, the circles represent the number of differently expressed transcripts regulated by
each virus (p value≤ 0.05, log2 fold change of≥ ±1). The numbers in the intersections of each circle represents the number of transcripts common to
the respective virus/es
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innate molecular signatures of published candidate vaccine
vectors
We compared the gene expression induced by each of the
6 poxviruses at 24 h to selected correlates of protection and
molecular signatures from previously published studies
(Table 4). The induction of multiple PRRs has been shown
to activate different immune pathways and thereby induce
a more polyvalent immune response [47, 48]. We identi-
fied differential expression of several genes involved in
pathogen recognition (Table 4). Several genes are common
to the innate and adaptive immune responses induced by
the poxviruses analysed here and other viral vectors ana-
lysed elsewhere (Table 4).Discussion
Novel avipoxviruses have been isolated in South Africa with
the goal of identifying novel vaccine vectors [26, 27]. It is
desirable to be able to select potential avipoxvirus vaccine
vectors without going through the process of making recom-
binant viruses and testing immunogenicity in animal models.
In this study, we compared the gene expression profiles in
mouse spleens 24 h after infection with six poxviruses from
3 different genera. All the viruses were grown in eggs and
the same purification methodology used. There have been
no comparisons of host responses to these six different pox-
viruses. One of the aims of this study was to determine if
one could select novel poxvirus vaccine vectors based on the
transcriptome analysis. It was hypothesized that if the
Table 2 Selection of up-regulated genes in mouse spleens in response to MVA, LSDV, CNPV, FWPV, PEPV and FeP2. Differences in
Log2 Fold Changes (between each virus and the control) are depicted.
Symbol Name Entrez MVA LSDV CNPV FWPV PEPV FeP2
Genes induced by LSDV alone
Oas1b 2′-5′ oligoadenylate synthetase 1B 23961 - 1.6 - - - -
Adar adenosine deaminase, RNA-specific 56417 - 1 - - - -
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 12608 - 1 - - - -
Ddx58 (RIG-1) DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 230073 - 1.3 - - - -
Grn granulin 14824 - 1.1 - - - -
Gvin1 GTPase, very large interferon inducible 1 74558 - 1.5 - - - -
Gm17757 GTPase, very large interferon inducible 1 pseudogene 100417829 - 1.5 - - - -
H2-T24 histocompatibility 2, T region locus 24 15042 - 1.2 - - - -
Ifi203 interferon activated gene 203 15950 - 1.1 - - - -
Ifitm3 interferon induced transmembrane protein 3 66141 - 1.4 - - - -
Ifi27l2a interferon, alpha-inducible protein 27 like 2A 76933 - 1.9 - - - -
Ly6i lymphocyte antigen 6 complex, locus I 57248 - 1 - - - -
Mif macrophage migration inhibitory factor 17319 - 1.1 - - - -
Myc myelocytomatosis oncogene 17869 - 1.1 - - - -
Nlrc5 NLR family, CARD domain containing 5 434341 - 1.8 - - - -
Slfn2 schlafen 2 20556 - 1.1 - - - -
Stat1 signal transducer and activator of transcription 1 20846 - 1.4 - - - -
Tap1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 21354 - 1.1 - - - -
Tap2 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 21355 - 1 - - - -
Trim25 tripartite motif-containing 25 217069 - 1 - - - -
Trim34b tripartite motif-containing 34B 434218 - 1.1 - - - -
Genes induced by CNPV, FWPV and MVA only, and not LSDV.
Casp1 caspase 1 12362 1.1 - 1.2 1.1 - -
Clec4a2 C-type lectin domain family 4, member a2 26888 1.2 - 1.5 1.1 - -
Ifi205 interferon activated gene 205 226695 1.4 - 1.6 1.8 - -
Prdx1 peroxiredoxin 1 18477 1 - 1 1.2 - -
Pnpt1 polyribonucleotide nucleotidyltransferase 1 71701 1.1 - 1.1 1.4 - -
Scimp SLP adaptor and CSK interacting membrane protein 327957 1.2 - 1.2 1.5 - -
Genes induced by avipoxviruses only (CNPV, FWPV, FEP2 and/ or PEPV)
Anxa1 annexin A1 16952 - - 1.6 1.8 - -
Apobec1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 11810 - - 1.2 1.2 - -
Ccl6 chemokine (C-C motif) ligand 6 20305 - - 1.3 1.3 - -
Ear2 eosinophil-associated, ribonuclease A family, member 2 13587 - - 1.3 1.5 - -
Hsbp1 heat shock factor binding protein 1 68196 - - 1.2 1.2 - -
Ighg Immunoglobulin heavy chain (gamma polypeptide) 380794 - - 1.5 1.6 - -
Ighg3 Immunoglobulin heavy constant gamma 3 380795 - - 1.3 1.2 - -
Lilrb3 leukocyte immunoglobulin-like receptor, subfamily B
(with TM and ITIM domains), member 3
18733 - - 1.1 1 - -
Marco macrophage receptor with collagenous structure 17167 - - 1 - 1.5 1.5
Pf4 platelet factor 4 56744 - - 1.2 1.1 - -
Pram1 PML-RAR alpha-regulated adaptor molecule 1 378460 - - 1.1 1.1 - -
Psma1 proteasome (prosome, macropain) subunit, alpha type 1 26440 - - 1.1 1.3 - -
Genes induced by FWPV only.
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Table 2 Selection of up-regulated genes in mouse spleens in response to MVA, LSDV, CNPV, FWPV, PEPV and FeP2. Differences in
Log2 Fold Changes (between each virus and the control) are depicted. (Continued)
Aif1 allograft inflammatory factor 1 11629 - - - 1.1 - -
Anxa2 annexin A2 12306 - - - 1.1 - -
Ddx18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 18 66942 - - - 1.1 - -
Dcn decorin 13179 - - - 1.5 - -
Fgl2 fibrinogen-like protein 2 14190 - - - 1.2 - -
Gsdmd gasdermin D 69146 - - - 1.2 - -
Myd88 myeloid differentiation primary response gene 88 17874 - - - 1.2 - -
Nos2 nitric oxide synthase 2, inducible 18126 - - - 1.1 - -
Nod1 nucleotide-binding oligomerization domain containing 1 107607 - - - 1 - -
Pdcd5 programmed cell death 5 56330 - - - 1.2 - -
Psmc6 proteasome (prosome, macropain) 26S subunit, ATPase, 6 67089 - - - 1 - -
Prmt1 protein arginine N-methyltransferase 1 15469 - - - 1 - -
Serpinb6b serine (or cysteine) peptidase inhibitor, clade B, member 6b 20708 - - - 1.2 - -
Genes induced by CNPV only.
Ctsl cathepsin L 13039 - - 1.1 - - -
Ighm immunoglobulin heavy constant mu 16019 - - 1.1 - - -
Ly96 lymphocyte antigen 96 17087 - - 1.2 - - -
Pomp proteasome maturation protein 66537 - - 1 - - -
Genes induced by LSDV AND MVA, but not by the AVIPOXVIRUSES
Hsh2d hematopoietic SH2 domain containing 209488 1.1 1.4 - - - -
Mov10 Moloney leukemia virus 10 17454 1.1 1.5 - - - -
Parp11 poly (ADP-ribose) polymerase family, member 11 101187 1 1.4 - - - -
Slfn8 schlafen 8 276950 1.2 1.5 - - - -
Other
Oas1a 2′-5′ oligoadenylate synthetase 1A 246730 1.5 2.7 1.6 1.4 - -
Oas1g 2′-5′ oligoadenylate synthetase 1G 23960 2.3 3.9 2.5 2.3 - -
Oas2 2′-5′ oligoadenylate synthetase 2 246728 2.1 3.4 2 1.6 - -
Oas3 2′-5′ oligoadenylate synthetase 3 246727 1.1 2.6 1.3 1 - -
Oasl1 2′-5′ oligoadenylate synthetase-like 1 231655 2.6 3.5 2.4 2.5 - -
Oasl2 2′-5′ oligoadenylate synthetase-like 2 23962 2 3.4 2 2 - -
Amica1 adhesion molecule, interacts with CXADR antigen 1 270152 - 1.1 - 1.1 - -
Angptl4 angiopoietin-like 4 57875 1.1 1.5 - 1.6 1.1 -
Asb13 ankyrin repeat and SOCS box-containing 13 142688 1.2 1 1.1 1.3 - -
Anxa4 annexin A4 11746 1.8 1.9 1.7 2.1 1.1 -
Apol9b apolipoprotein L 9b 71898 2.3 2.7 2.6 2.4 - -
Bst2 bone marrow stromal cell antigen 2 69550 2.3 3 2.1 2.2 - -
Casp4 caspase 4, apoptosis-related cysteine peptidase 12363 1.9 1.6 1.9 2 - -
Ctsc cathepsin C 13032 1.1 1.1 - 1.1 - -
Cd274 CD274 antigen 60533 1.9 2.3 1.6 2.1 1.2 -
Cd5l CD5 antigen-like 11801 1.2 1.5 1.4 1.1 - -
Cd69 CD69 antigen 12515 1.8 1.8 1.5 1.7 - -
Ccl2 (MCP1) chemokine (C-C motif) ligand 2 20296 3.5 3.3 2.9 3.3 2.8 -
Ccl3 (MIP-1α) chemokine (C-C motif) ligand 3 20302 2 2.1 2.3 2 1.4 -
Ccl7 chemokine (C-C motif) ligand 7 20306 3 2.9 2.6 2.9 2.7 1.5
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Table 2 Selection of up-regulated genes in mouse spleens in response to MVA, LSDV, CNPV, FWPV, PEPV and FeP2. Differences in
Log2 Fold Changes (between each virus and the control) are depicted. (Continued)
Ccr5 chemokine (C-C motif) receptor 5 12774 1.1 1.5 1.3 1.3 - -
Ccrl2 chemokine (C-C motif) receptor-like 2 54199 - 1.5 1.2 1.4 - -
Cxcl10 (IP-10) chemokine (C-X-C motif) ligand 10 15945 2.7 3 2.2 2.8 1.7 -
Cxcl11 (I-TAC) chemokine (C-X-C motif) ligand 11 56066 4.5 4.4 3.4 4.3 1.5 -
Cxcl9 (MIG) chemokine (C-X-C motif) ligand 9 17329 2.1 2.3 - 1.8 - -
Chi3l3 chitinase 3-like 3 12655 - 1.2 1.4 1.6 - -
Csf2rb2 colony stimulating factor 2 receptor, beta 2, low-affinity
(granulocyte-macrophage)
12984 - 1.5 - 1.7 - -
C1qa complement component 1, q subcomponent, alpha polypeptide 12259 - 1.1 1 - - -
C2 complement component 2 (within H-2S) 12263 1.5 1.8 1.7 1.6 1 -
Cfb complement factor B 14962 2.2 2.6 1.6 2 1 -
Cdkn1a (P21) cyclin-dependent kinase inhibitor 1A 12575 1.7 2 1.5 2 1.2 -
Cstb cystatin B 13014 1.4 1 1.5 1.5 - -
Cst7 cystatin F (leukocystatin) 13011 1.2 1.4 1.1 1.4 - -
Cmpk2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 22169 1.3 2 1.3 1.3 - -
Cycs cytochrome c, somatic 13063 - 1.1 - 1.1 - -
Ctla2a cytotoxic T lymphocyte-associated protein 2 alpha 13024 1.1 1 1.1 1.3 - 1.4
Ddx60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 234311 1.7 2.6 1.5 1.4 - -
Dhx58 (LGP2) DEXH (Asp-Glu-X-His) box polypeptide 58 80861 1.7 2.5 1.6 1.5 - -
Dram1 DNA-damage regulated autophagy modulator 1 71712 1.2 1.4 - 1.3 - -
Ddit4 DNA-damage-inducible transcript 4 74747 1.2 1.2 1.8 1.3 1.4 -
Eif2ak2 (PKR) eukaryotic translation initiation factor 2-alpha kinase 2 19106 1.1 2.1 1.1 1.1 - -
Daxx Fas death domain-associated protein 13163 2 2.3 1.7 1.9 - -
Fcgr1 Fc receptor, IgG, high affinity I 14129 2.4 2.6 2.4 2.6 1.4 -
Fcgr4 Fc receptor, IgG, low affinity IV 246256 2.5 3.6 2.8 2.9 1.8 -
Fpr1 formyl peptide receptor 1 14293 1.3 1.1 1.4 1.4 - -
Fpr2 formyl peptide receptor 2 14289 1.8 1.5 1.7 1.9 - -
Glipr2 GLI pathogenesis-related 2 384009 1.4 1.5 1.1 1.5 - -
Gp49a glycoprotein 49 A 14727 2.6 2.4 2.7 2.7 1.9 2
Gca grancalcin 227960 1.2 1.3 1.4 1.6 - -
Gzma granzyme A 14938 1.8 1.8 2.2 2 - -
Gzmb granzyme B 14939 3.7 4.7 4.1 4.2 2.4 -
Gadd45b growth arrest and DNA-damage-inducible 45 beta 17873 1.3 1.5 1.2 1.5 - -
Gbp1 guanylate binding protein 1 14468 2.1 2.7 1.6 2.5 - -
Gbp11 guanylate binding protein 11 634650 3.9 4.5 2.9 4.2 1.6 -
Gbp2 guanylate binding protein 2 14469 2.3 2.8 1.5 2.7 - -
Gbp3 guanylate binding protein 3 55932 1.6 1.8 1.2 1.6 - -
Gbp4 guanylate binding protein 4 17472 2.1 2.7 1.3 2.4 - -
Gbp5 guanylate binding protein 5 229898 2 2.8 1.3 2.2 1.1 -
Gbp7 guanylate binding protein 7 229900 1.6 2.2 1.2 1.7 - -
Gbp10 guanylate-binding protein 10 626578 2.1 3.2 1.3 1.9 - -
Gbp8 guanylate-binding protein 8 76074 1.3 1.4 1.4 2.1 - -
Gbp9 guanylate-binding protein 9 236573 1.2 1.9 1 1.3 - -
Hp haptoglobin 15439 1.2 1.8 1.7 1.9 1.3 1.3
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Table 2 Selection of up-regulated genes in mouse spleens in response to MVA, LSDV, CNPV, FWPV, PEPV and FeP2. Differences in
Log2 Fold Changes (between each virus and the control) are depicted. (Continued)
Hspa1b heat shock protein 1B 15511 2.3 2.9 2.4 2.5 - -
H2-Q4 histocompatibility 2, Q region locus 4 15015 1 1.2 - 1.2 - -
H2-Q6 histocompatibility 2, Q region locus 6 110557 1 1 - 1.1 - -
H2-T22 histocompatibility 2, T region locus 22 15039 1 1.3 - - - -
H2-T23 histocompatibility 2, T region locus 23 15040 1 1.3 - 1 - -
Irgm1 immunity-related GTPase family M member 1 15944 1.4 2.3 1.1 1.4 - -
Irgm2 immunity-related GTPase family M member 2 54396 1 1.7 - 1.2 - -
Irg1 immunoresponsive gene 1 16365 2.6 2.5 1.9 2.5 1.6 -
Ifi202b interferon activated gene 202B 26388 2.4 2.6 2.1 2.2 - -
Ifi204 interferon activated gene 204 15951 3.3 4 3.2 3.9 - -
Igtp interferon gamma induced GTPase 16145 1.4 2.2 1 1.8 - -
Ifitm6 interferon induced transmembrane protein 6 213002 1.8 1.9 2.4 2.3 1.6 1.5
Ifih1 (MDA5) interferon induced with helicase C domain 1 71586 1.3 2.1 1.2 1.2 - -
Iigp1 interferon inducible GTPase 1 60440 1.7 2.9 1.2 1.9 - -
Irf1 interferon regulatory factor 1 16362 - 1.3 - 1.1 - -
Irf7 interferon regulatory factor 7 54123 1.7 2.9 1.7 1.1 - -
Ifi35 interferon-induced protein 35 70110 1.1 1.5 1.1 1.2 - -
Ifi44 interferon-induced protein 44 99899 2 2.5 1.8 1.6 - -
Ifi44l interferon-induced protein 44 like 15061 2.1 2.9 2 2 - -
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 15957 2.2 3.3 2 1.7 - -
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 15958 1.8 2.5 1.8 1.7 - -
Il1a interleukin 1 alpha 16175 1.9 2 2.2 2.3 1.8 -
Il1f9 interleukin 1 family, member 9 215257 1.3 1.6 1.7 1.8 1.2 1
Il1rn interleukin 1 receptor antagonist 16181 1.3 1.1 - 1.2 - -
Il12rb1 interleukin 12 receptor, beta 1 16161 2 2.4 1.7 2.1 1.1 -
Il12rb2 interleukin 12 receptor, beta 2 16162 1.2 1.3 1.3 1.3 - -
Il15 interleukin 15 16168 1.1 1.3 1.2 1 - -
Il15ra interleukin 15 receptor, alpha chain 16169 1.8 1.9 1.5 1.8 1.2 -
Il18bp interleukin 18 binding protein 16068 1.2 1.7 1.3 1.5 - -
Il2ra interleukin 2 receptor, alpha chain 16184 1.1 1.2 - 1.3 1.1 -
Il33 interleukin 33 77125 - 1 - 1.1 - -
Isg15 ISG15 ubiquitin-like modifier 100038882 1.6 2.2 1.5 1.4 - -
Klrk1 killer cell lectin-like receptor subfamily K, member 1 27007 1.5 1.7 1.6 1.5 - -
Lgals9 lectin, galactose binding, soluble 9 16859 1.2 1.6 1.1 1.2 - -
Lgals3bp lectin, galactoside-binding, soluble, 3 binding protein 19039 1.2 1.7 1.1 - - -
Lilrb4 leukocyte immunoglobulin-like receptor, subfamily B, member 4 14728 1.6 1.5 1.7 1.7 1.1 -
Lcn2 lipocalin 2 16819 1.4 1.6 2.2 2.2 1.4 1.7
Ly6a lymphocyte antigen 6 complex, locus A 110454 1.7 1.9 1.2 1.3 - -
Ly6c1 lymphocyte antigen 6 complex, locus C1 17067 1.8 2.2 1.9 1.9 - -
Ly6c2 lymphocyte antigen 6 complex, locus C2 100041546 1.3 1.6 1.3 1.1 - -
Ly6g lymphocyte antigen 6 complex, locus G 546644 - 1.7 2.5 2.2 - -
Msr1 macrophage scavenger receptor 1 20288 2.3 2 2 2.2 1.4 1.1
Mmp13 matrix metallopeptidase 13 17386 2.7 2.6 2.4 2.4 1.5 -
Mmp19 matrix metallopeptidase 19 58223 1.9 2 2 2 1.5 1.2
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Table 2 Selection of up-regulated genes in mouse spleens in response to MVA, LSDV, CNPV, FWPV, PEPV and FeP2. Differences in
Log2 Fold Changes (between each virus and the control) are depicted. (Continued)
Mmp25 matrix metallopeptidase 25 240047 - 1 - 1.1 - -
Mmp8 matrix metallopeptidase 8 17394 2.7 3 3.1 3.4 2.5 2.8
Ms4a4a membrane-spanning 4-domains, subfamily A, member 4A 666907 2.6 2.7 2.6 2.5 1.5 1.1
Ms4a4c membrane-spanning 4-domains, subfamily A, member 4C 64380 1.2 1.5 1.2 1 - -
Ms4a4d membrane-spanning 4-domains, subfamily A, member 4D 66607 1.6 1.5 1.6 1.8 - -
Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 73656 1.1 1.1 1.2 1.2 - -
Ms4a6d membrane-spanning 4-domains, subfamily A, member 6D 68774 3.2 3.5 3.1 3.3 - -
Ms4a7 membrane-spanning 4-domains, subfamily A, member 7 109225 1.7 1.4 2 1.9 1.4 -
Mlkl mixed lineage kinase domain-like 74568 2.1 2.7 2 2.3 - -
Mnda myeloid cell nuclear differentiation antigen 381308 1.8 1.8 1.6 1.7 - -
Mndal myeloid nuclear differentiation antigen like 1E + 08 1.1 1.3 1.1 1.2 - -
Mx1 myxovirus (influenza virus) resistance 1 17857 3.2 3.9 3 2.8 - -
Mx2 myxovirus (influenza virus) resistance 2 17858 2.7 3.7 2.1 2.2 - -
Nampt nicotinamide phosphoribosyltransferase 59027 1.7 1.9 1.5 2 - -
Nmi N-myc (and STAT) interactor 64685 1.3 1.6 1.1 1.5 - -
Prf1 perforin 1 (pore forming protein) 18646 1.2 1.4 1.1 1.2 - -
Phf11a PHD finger protein 11A 219131 1.2 1.4 1.1 1.1 - -
Phf11b PHD finger protein 11B 236451 2 1.8 1.7 1.8 - -
Phf11c PHD finger protein 11C 628705 2 2.4 1.7 1.7 - -
Phf11d PHD finger protein 11D 219132 2.4 2.9 2.4 2.4 1.1 -
Plac8 placenta-specific 8 231507 1.3 1.7 - 1.3 - -
Parp10 poly (ADP-ribose) polymerase family, member 10 671535 1.2 1.5 - 1.2 - -
Parp12 poly (ADP-ribose) polymerase family, member 12 243771 1.5 2.5 1.3 1.6 - -
Parp14 poly (ADP-ribose) polymerase family, member 14 547253 1.1 1.7 - 1 - -
Parp9 poly (ADP-ribose) polymerase family, member 9 80285 1.3 1.9 1.1 1.2 - -
Psme1 proteasome (prosome, macropain) 28 subunit, alpha 19186 - 1.1 - 1 - -
Psma7 proteasome (prosome, macropain) subunit, alpha type 7 26444 - 1.1 - 1.1 - -
Psmb10 proteasome (prosome, macropain) subunit, beta type 10 19171 1.1 1.4 - 1.3 - -
Psmb8 proteasome (prosome, macropain) subunit, beta type 8
(large multifunctional peptidase 7)
16913 - 1.4 - 1.1 - -
Pyhin1 pyrin and HIN domain family, member 1 236312 1.7 1.8 1.5 1.4 - -
Pydc3 pyrin domain containing 3 100033459 1.9 2.4 1.7 1.5 - -
Pydc4 pyrin domain containing 4 623121 2.9 3.4 2.2 1.9 - -
Ppa1 pyrophosphatase (inorganic) 1 67895 1.3 2.1 - 1.5 - -
Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 27273 1.5 1.1 1.7 1.4 1.8 1.8
Rtp4 receptor transporter protein 4 67775 1.4 2.2 1.2 1.1 - -
Retnlg resistin like gamma 245195 1.1 1.3 1.5 1.6 1.4 1.6
Rnf19b ring finger protein 19B 75234 - 1.2 - 1.1 - -
Rnf213 ring finger protein 213 672511 1.4 2.2 1 1 - -
Slfn1 schlafen 1 20555 1.8 1.9 1.3 1.5 - -
Slfn3 schlafen 3 20557 1.3 1.7 1.5 1.7 - -
Slfn4 schlafen 4 20558 1.9 3 2 1.8 - -
Slfn5 schlafen 5 327978 1.5 2.4 1.4 1.1 - -
Slfn9 schlafen 9 237886 1.5 2.4 1.4 1.7 - -
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Table 2 Selection of up-regulated genes in mouse spleens in response to MVA, LSDV, CNPV, FWPV, PEPV and FeP2. Differences in
Log2 Fold Changes (between each virus and the control) are depicted. (Continued)
Serpina3f serine (or cysteine) peptidase inhibitor, clade A, member 3 F 238393 1.9 2.7 1.3 2.2 1.3 -
Serpinb9 serine (or cysteine) peptidase inhibitor, clade B, member 9 20723 1.3 1.1 1.1 1.4 - -
Serpinb9b serine (or cysteine) peptidase inhibitor, clade B, member 9b 20706 1.2 1 1.1 - - -
Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 18787 1.1 - - 1 - -
Stat2 signal transducer and activator of transcription 2 20847 1.4 1.9 1.2 1.5 - -
Slamf8 SLAM family member 8 74748 - 1.1 - 1.2 - -
Slc15a3 solute carrier family 15, member 3 65221 - 1.3 - 1.1 - -
Slc25a22 solute carrier family 25 (mitochondrial carrier, glutamate), member 22 68267 - 1.2 1 1.2 - -
Socs1 suppressor of cytokine signaling 1 12703 1.6 2.2 - 1.9 - -
Socs2 suppressor of cytokine signaling 2 216233 1 1.4 - 1.8 - -
Tgtp1 T cell specific GTPase 1 21822 - 1.4 - 1.1 - -
Tgtp2 T cell specific GTPase 2 1.00E + 08 1.6 2.7 - 1.5 - -
Trex1 three prime repair exonuclease 1 22040 - 1.2 - 1 - -
Timp1 tissue inhibitor of metalloproteinase 1 21857 2.8 2.9 2.4 2.9 1.8 1.6
Tlr13 toll-like receptor 13 279572 1.4 1 1.7 1.5 1 -
Tlr3 toll-like receptor 3 142980 1 1.4 1.2 1.1 - -
Tlr7 toll-like receptor 7 170743 1.1 1.2 1.2 - - -
Tlr8 toll-like receptor 8 170744 1.1 1.1 1.3 1 - -
Trafd1 TRAF type zinc finger domain containing 1 231712 1.1 1.6 1 1.1 - -
Trem3 triggering receptor expressed on myeloid cells 3 58218 1.1 1.4 1.2 1.5 - -
Trim12c tripartite motif-containing 12C 319236 - 1.5 1.2 1.3 - -
Trim21 tripartite motif-containing 21 20821 1.1 1.3 - 1.4 - -
Trim30a tripartite motif-containing 30A 20128 1.3 2.1 - 1.1 - -
Trim30c tripartite motif-containing 30C 434219 2.6 3.4 2.5 2.2 - -
Trim30d tripartite motif-containing 30D 209387 3.1 3.5 3.4 2.7 1.4 -
Wars tryptophanyl-tRNA synthetase 22375 1.1 1.6 - 1.4 - -
Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10 22035 2 2.3 2 1.9 - -
Usp18 ubiquitin specific peptidase 18 24110 2.2 3.1 2 1.8 - -
Zbp1 Z-DNA binding protein 1 58203 1.9 2.7 1.3 1.6 - -
Italics: Genes induced by LSDV alone
Italics and underlined: Genes induced by CNPV, FWPV and MVA only, and not LSDV
Bold: Genes induced by Avipoxviruses only (CNPV, FWPV, FeP2 and/ or PEPV)
Bold and Italics: Genes induced by FWPV only
Bold and underlined: Genes induced by CNPV only
Underlined: Genes induced by LSDV and MVA, but not by the Avipoxviruses
Offerman et al. BMC Genomics  (2015) 16:510 Page 11 of 20transcriptomes were identical then it was unlikely that they
would differ as vaccine vectors. The complex model of the
mouse spleen was selected because the spleen is rich in im-
mune cells and the immune response is a complex inter-
action between different types of cells and their proteins
which would not be reflected in in vitro models. Although
in vitro expression studies have provided useful information,
gene expression profiles performed in cell culture may not
accurately reflect the changes that occur as result of infec-
tion in vivo. It is anticipated that different poxviruses will
have different properties that will relate to their ability toact as adjuvants driving the immune response to the vac-
cine protein towards a particular type of immune response.
Unsupervised hierarchical clustering differentiates be-
tween the observed responses to the six poxviruses,
grouping CNPV and MVA together and FWPV in a sep-
arate cluster (more closely related to CNPV and MVA
than to LSDV) (Fig. 1). FeP2 and PEPV group together in
a cluster that is separate from the other four viruses
(Fig. 1). This grouping is quite different from phylogenetic
relationships established by DNA sequence comparisons
[27]. It is also not dependent on the viral morphogenesis
Table 3 Selection of down-regulated genes in mouse spleens in response to MVA, LSDV, CNPV, FWPV, PEPV and FeP2. Differences
in Log2 Fold Changes (between each virus and the control) are depicted
Symbol Name Entrez MVA LSDV CNPV FWPV PEPV FeP2
Genes down-regulated by LSDV ALONE
Adamdec1 ADAM-like, decysin 1 58860 - −1.1 - - - -
Cd59a CD59a antigen 12509 - −1.2 - - - -
Cd7 CD7 antigen 12516 - −1.1 - - - -
Esm1 endothelial cell-specific molecule 1 71690 - −1.1 - - - -
Igfbp3 insulin-like growth factor binding protein 3 16009 - −1 - - - -
Igk immunoglobulin kappa chain complex 243469 - −1 - - - -
Lilra5 leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5 232801 - −1.1 - - - -
Prkcg protein kinase C, gamma 18752 - −1 - - - -
Genes down-regulated by MVA alone
Ctsf cathepsin F 56464 −1.1 - - - - -
Depdc1a DEP domain containing 1a 76131 −1.1 - - - - -
Diap3 diaphanous homolog 3 (Drosophila) 56419 −1.1 - - - - -
Hmmr (CD168) hyaluronan mediated motility receptor (RHAMM) 15366 −1 - - - - -
Tlr11 toll-like receptor 11 239081 −1 - - - - -
Genes down-regulated by lsdv and MVA, BUT NOT BY CNPV and FWPV
Ccl21a chemokine (C-C motif) ligand 21A (serine) 18829 −1.3 −1.7 - - - -
Ccl21b chemokine (C-C motif) ligand 21B (leucine) 100042493 −1.2 −1.7 - - - -
Ccl21c chemokine (C-C motif) ligand 21C (leucine) 65956 −1.2 −1.6 - - - -
Kel Kell blood group 23925 −1.5 −1.5 - - - -
Slc12a2 solute carrier family 12, member 2 20496 −1 −1 - - - -
Timd4 T cell immunoglobulin and mucin domain containing 4 276891 −1.1 −1.3 - - - -
Genes down-regulated by CNPV, FWPV AND MVA ONLY, and not LSDV.
Tspan33 tetraspanin 33 232670 −1.6 - −1.3 −1.1 - -
OTHER
Abca9 ATP-binding cassette, sub-family A (ABC1), member 9 217262 −1.3 −1.5 - −1.1 - -
Aplnr apelin receptor 23796 −1.4 −1.5 −1.2 −1.2 - -
Cd209a CD209a antigen 170786 −1.7 −2.2 −1.1 −1.5 - -
Cd209b CD209b antigen 69165 −1.2 −1.3 - - - -
Cldn13 claudin 13 57255 −1.5 −1.2 −1.1 - - -
Emr4 EGF-like module containing, mucin-like, hormone receptor-like sequence 4 52614 −1.4 −1.8 −1.1 −1.5 −1.3 -
Fcamr Fc receptor, IgA, IgM, high affinity 64435 −1.1 - −1.5 - - -
Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide 14128 −2.6 −3 −2.4 −2.5 −2.2 −1.3
H2-M2 histocompatibility 2, M region locus 2 14990 −1 −1.4 −1 −1 −1.1 -
Hs3st2 heparan sulfate (glucosamine) 3-O-sulfotransferase 2 195646 −1.4 −1.3 −1 −1 - -
Ifi27l1 interferon, alpha-inducible protein 27 like 1 52668 −1.4 −1.3 - - - -
Mgst3 microsomal glutathione S-transferase 3 66447 −1.6 −1 - −1 - -
Slc16a10 solute carrier family 16 (monocarboxylic acid transporters), member 10 72472 −1.4 - - −1.1 - -
Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 20528 −1.7 −1 - −1.1 - -
Slc38a5 solute carrier family 38, member 5 209837 −1.4 −1.2 −1 - - -
Slc6a20a solute carrier family 6 (neurotransmitter transporter), member 20A 102680 −1.4 −1.3 −1 −1 - -
Tfrc transferrin receptor 22042 −1.2 - - - - -
Tspan8 tetraspanin 8 216350 −1.4 - - −1 - -
Italics genes down-regulated by LSDV alone
Bold Genes down-regulated by MVA alone
Underlined genes down-regulated by LSDV and MVA, but not by avipoxviruses
Italics and underlined genes down-regulated by CNPV, FWPV and MVA only, and not LSDV
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onstrated to infect mammalian cells [28] and progress to a
late stage in morphogenesis [28, 49] whereas FeP2 [50]
and CNPV have a block prior to DNA replication [51]. It
is noted that infectivity studies have not been done in
mouse spleens and that this may be different to published
data on other mammalian cells. A further study is needed
to determine if PEPV and FeP2 infect the same number of
cells in the mouse spleen as the other viruses.
Amongst the four avipoxviruses analysed here, the
greatest difference in host responses was expected be-
tween CNPV and FWPV, as on a genomic level, these vi-
ruses are significantly divergent with amino acid identity
between ORF homologues (55–74 %) being similar to
that observed between different ChPV genera [52]. We did
not expect to see such significant differences between the
host responses induced by FeP2 and PEPV which share
94.4 % nucleotide identity with each other and 85.3 and
84.0 % nucleotide identity with FWPV respectively [27].
Since avipoxviruses are restricted to avian hosts, one would
anticipate fewer differences between the mammalian host
responses induced by them as it is highly likely that their
proteins are not as functional in mammalian cells as those
of MVA and LSDV. However we show that three relatively
closely related avipoxviruses (FWPV, FeP2 and PEPV)
induce significant differences in gene expression in the
host. FWPV induced the strongest host response in mice
whereas FeP2 infection resulted in remarkably little change
in host gene expression. A vaccine vector with low host re-
activity, such as observed with PEPV or FeP2, might have
the advantage of being a good vector to include adjuvant
genes to enhance immunogenicity. Further investigation is
needed to determine if there would be a good immune re-
sponse to foreign antigens expressed by these vectors.
Previous in vitro studies with VACV, MVA and NYVAC
have shown more host genes to be down-regulated than
up-regulated [11–14]; however, this was not the case in
other poxviruses, including cowpox virus (CPXV) [53],
monkeypox virus (MPXV) [53] or ALVAC [15]. Unlike
our study, done in a mouse model, all these studies were
done in cell culture. We show that fewer genes are down-
regulated than up-regulated in response to in vivo infec-
tion at 24 h post infection (Table 1). For each poxvirus
tested several of the dysregulated mouse genes are not yet
annotated suggesting biological roles for unannotated
genes and highlighting the importance of further func-
tional analysis and annotation of the mouse genome. Con-
trary to in vitro studies, MVA caused more transcripts to
be up-regulated than down-regulated in mouse spleens.
MVA infection did, however, result in a greater number of
down-regulated transcripts compared to LSDV, FWPV
and CNPV.
MVA and LSDV induced the down-regulation of several
genes that were not affected by the avipoxviruses testedincluding three forms of the chemokine CCL21 (Ccl21a,
Ccl21b, Ccl21c) which are potent chemoattractants for
lymphocytes and dendritic cells [40] (Table 3). VACVA41L
encodes a chemokine binding protein which binds and
inhibits CCL21 [54] and deletion mutants lacking the
A41L gene, induce stronger virus-specific CD8+ T-cell re-
sponses [54, 55]. LSDV does not have a homolog of the
A41L gene; there must be other mechanisms that mam-
malian poxviruses have evolved to evade the effects of
CCL21, which is clearly important for the host in clearing
poxvirus infection. In selecting/designing a vaccine vector
it would be desirable to use a virus which lacks A41L and
does not down regulate CCL21 if a strong CD8+ T cell re-
sponse is required.
Interestingly, MVA, LSDV, FWPV and CNPV all
down-regulated the gene encoding the murine homo-
log for DC-specific ICAM-3–grabbing nonintegrin (DC
SIGN) (Cd209a). Furthermore MVA, LSDV and FWPV
down-regulated an additional DC SIGN homolog,
CD209b (SIGNR1) (Table 3).
LSDV has a host-range restricted to ruminants and is
currently being investigated as an HIV vaccine vector
[3, 56]. LSDV caused the most significant response in
mice compared to the other poxviruses, both in terms of
the number of up-regulated genes and the magnitude
and breadth of the type I Interferon response (Fig. 4).
LSDV clustered independently from the avipoxviruses
and MVA. LSDV up-regulated genes are involved in the
antigen processing and presentation pathway (H2-T24,
Tap1 and Tap2). Furthermore, LSDV uniquely up-
regulated the gene encoding macrophage migration in-
hibitory factor (Mif ), which is important in both macro-
phage function and T-cell immunity [57], and Ddx58,
otherwise known as RIG-I (retinoic acid-inducible gene
1), which recognises viral RNA, activating downstream
signalling pathways that facilitate type I IFN production
[58]. The up-regulation of RIG-I may, in part, be respon-
sible for the increased type I IFN response seen in
LSDV-infected mice. Another one of the many genes
uniquely up-regulated by LSDV was the transcription
factor (Myc) that promotes growth, proliferation and
apoptosis [59]. Myc has been shown to be up-regulated
in response to infection with NYVAC and MVA in HeLa
cells [13]. The absence of Myc up regulation in mouse
spleens by MVA was unexpected. In a study done in
Rhesus macaques rLSDV vector expressing an HIV poly-
protein was immunogenic at a dose 1000-fold lower
than that of rMVA. Both CD4+ and CD8+ responses
were induced, rather than a predominance of CD4+ T
cells observed typically for poxvirus vectors [3].
Both LSDV and MVA up-regulated a cellular homolog
of Moloney Leukemia Virus 10 (Mov10), which has
been shown to inhibit retrovirus replication and infectiv-































































Fig. 3 Heatmap (a) and radial plot (b) depicting the differences in the type I Interferon response induced by canarypox virus (CNPV), pigeonpox
(FeP2), fowlpox virus (FWPV), lumpy skin disease virus (LSDV), modified vaccinia Ankara (MVA) and penguinpox virus (PEPV). Fig. 3. a represents
the log2 fold change (FC) induction of the different genes up-regulated in the six samples compared to the control. A log2FC of 0 is given where
genes are not present over the cut off (±1). Unsupervised hierarchical clustering of the samples is represented by dendograms. Clustering analysis
and heatmap was performed in the R package, gplots (Warnes, 2009). Fig. 3. b shows a radial plot depicting the magnitude and breadth of the
type I interferon response induced by the six viruses. The distance from the centre of the plot indicates log2-fold change (ranging from −2 to 4)
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vaccine vectors encoding Gag proteins. Avipoxviruses may
therefore be better vectors than MVA or LSDV for the ex-
pression of Gag.
CNPV and FWPV induce the up regulation of two im-
munoglobulin genes (Ighg and Ighg3 (IgG3)) with CNPV
up regulating a third, Ighm (Fig. 4b). All six viruses
down-regulated the IgE FC receptor alpha (Fcer2a) poly-
peptide gene. IgE is involved in allergic responses and
not vaccine responses. Antibodies of the same epitope
specificity but of a different subclass can have different
antibody effector functions [61]. In a recent comparison
of the immune responses resulting from the partially ef-
fective clinical RV144 HIV-1 trial and the ineffective
VAX003 trial, it was shown that HIV-1–specific IgG3 anti-
bodies were correlated with decreased risk of HIV-1 infec-
tion in the RV144 trial. It is suggested that the canarypox
virus, ALVAC-HIV (vCP1521) prime component of RV144
may have stimulated different antibody subclasses, specifi-
cally IgG3, compared to the protein-only vaccine (VAX003)
[61]. The up regulation of IgG3 specifically by FWPV and
CNPV in vivo, suggests that these two avipoxvirus vectors
may be involved in stimulation of the clinically important
IgG3 antibody subclass. Up regulation of IgG3 was notdetected in ALVAC-infected monocyte derived dendritic
cells (MDDCs) [15]; this potentially significant finding is an
example of the importance of in vivo testing.
Type I IFN responses have been highlighted in previ-
ous studies investigating host gene expression changes
in response to different host-restricted poxviruses [14,
15]. Type I IFN induces an extensive range of interferon
stimulated genes (ISGs) with various anti-viral functions
(reviewed here: [62]). In concurrence with previous stud-
ies of poxvirus-induced host responses [14, 15], Type I
IFN responses were initiated by MVA, LSDV, CNPV and
FWPV, with LSDV inducing the strongest response in
mice (Fig. 4), followed by CNPV and FWPV, with MVA
inducing a relatively low IFN response. FeP2 and PEPV in-
duced very little ISG expression. The observed enhanced
type I IFN-specific and other immune responses elicited
by LSDV, FWPV and CNPV compared to MVA may be
due to the absence of virus-encoded immunomodulators
in these viruses which could still be present in MVA. Our
results suggest that LSDV may be more immunogenic
than FWPV and CNPV in mice. It is not known whether
this greater IFN-response induced by LSDV in compari-
son to avipoxviruses would lead to enhanced clearance of
the virus and a decreased immune response to any
Fig. 4 a T-cell specific responses and 4b) B-cell specific responses up- or down-regulated in mouse spleens in response to canarypox virus (CNPV),
pigeonpox (FeP2), fowlpox virus (FWPV), lumpy skin disease virus (LSDV), modified vaccinia Ankara (MVA) and penguinpox virus (PEPV). The log2
fold changes of significantly differentially expressed (p value≤ 0.05) genes involved in the respective types of responses are compared. A value of
0 indicates that no change was observed compared to mock infected mouse spleens. A positive value depicts upregulated genes and a negative
value depicts down-regulated genes
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sponse would result in an improved immune response to
the transgene, should LSDV be used as a vaccine vector.
Toll-like receptors are important regulators of the innate
immune system. Poxviruses are recognized by a number
of different pathogen recognition receptors (PRRs) with
innate immune sensing patterns differing considerably be-
tween species and even between different derivatives of
the same parent species (VACV, MVA and NYVAC) [23].
In our study we show that TLR13, TLR3 and TLR8 are
up-regulated by four poxviruses analysed (CNPV, FWPV,
MVA and LSDV). In addition, TLR7 is up-regulated by
CNPV, MVA and LSDV but not by FWPV (Table 2). Up
regulation of TLR 3, which detects double stranded RNA,
has been observed in response to MVA, but not NYVAC
infection of MDDCs [14]. IFNs have been shown to up
regulate TLR gene expression in viral infections [63]. Here
we have established that CNPV, FWPV, MVA and LSDV
all induce significant type I IFN responses and we suggestthat the up regulation of TLR expression may be a result
of this.
MVA, FWPV and CNPV all up regulate the protease
Caspase 1 (Casp1) whereas LSDV does not (Fig. 4). Casp1
dependent programmed cell death (pyroptosis), unlike
apoptosis, is a pro-inflammatory process that has recently
been recognised as important for the control of microbial
infections [64]. All of MVA, FWPV, CNPV and LSDV also
significantly up-regulated caspase 4 (casp 4) (historically
called caspase 11 in the mouse) (gene lists reference)
which is required for the maturation of the pro-proteins
of IL-1b and IL-18 (proIL-1b, proIL-18) and plays an im-
portant role in the activation of caspase-1 in inflamma-
some complexes, and therefore inflammation [65]. The
correlation of caspase up-regulation with either apoptosis
or pyroptosis is still to be assessed.
Application of the systems biology approach to vac-
cines and determination of innate immune signatures
has proven useful in predicting the immunogenicity of
Table 4 Comparison of early poxvirus-induced immune responses to selected innate molecular signatures of existing vaccine
vectors. Differences in Log2 Fold Changes (between each virus and the control) are depicted
description MVA LSDV CNPV FWPV PEPV FeP2 Evidence References
Innate immune response
Pathogen recognition
Tlr13 toll-like receptor 13 1.4 1.0 1.7 1.5 1.0 -
Tlr3 toll-like receptor 3 1 1.4 1.2 1.1 - - Merck Ad5/HIV [22]
Tlr7 toll-like receptor 7 1.1 1.2 1.2 - - - YF-17D, LAIV [20, 21]
Tlr8 toll-like receptor 8 1.1 1.1 1.3 1.0 - - Merck Ad5/HIV [22]
Tlr11 toll-like receptor 11 −1.0 - - - - -
Ddx58 (RIG-I) RIG-I-like receptor - 1.3 - - - - YF-17D [20]
Cd209a (DC
SIGN)
CD209a antigen −1.7 −2.2 −1.1 −1.5 - -
Cd209b (DC
SIGN)
CD209b antigen −1.2 −1.3 - - - -
Ifih1 (MDA5) RIG-I-like receptor 1.3 2.1 1.2 1.2 - - YF-17D [20]
Zbp1 (DAI) cytoplasmic double-stranded DNA
sensor
1.9 2.7 1.3 1.6 - -
Dhx58 (LGP2) RIG-I-like receptor 1.7 2.5 1.6 1.5 - - YF-17D [20]
Eif2ak2 (PKR) eukaryotic translation initiation factor
2-alpha kinase 2 (protein kinase R)
1.1 2.1 1.1 1.1 - - YF-17D [20]
Genes associated with the innate immune response of viral vectors
Cxcl10 (IP-10) chemokine (C-X-C motif) ligand 10 2.7 3 2.2 2.8 1.7 - Significantly upregulated in response
to YF-17D, Merck Ad5/HIV, TIV
[20−22]
Mx1 myxovirus (influenza virus) resistance 1 3.2 3.9 3 2.8 - - YF-17D [20]
Il-1α interleukin 1 alpha 1.9 2 2.2 2.3 1.8 - Significantly upregulated in
response to YF-17D
Isg15 ISG15 ubiquitin-like modifier 1.6 2.2 1.5 1.4 - - Merck Ad5/HIV [22]
Stat1 signal transducer and activator
of transcription 1
- 1.4 - - - - YF-17D, Merck Ad5/HIV, LAIV [20−22]
Cxcl11 (I-TAC) chemokine (C-X-C motif) ligand 11 4.5 4.4 3.4 4.3 1.5 - Merck Ad5/HIV [22]
Ccr5 chemokine (C-C motif) receptor 5 1.1 1.5 1.3 1.3 - - Merck Ad5/HIV [22]
Gbp7 guanylate binding protein 7 1.6 2.2 1.2 1.7 - - Merck Ad5/HIV [22]
Irf1 interferon regulatory factor 1 - 1.3 - 1.1 - - Merck Ad5/HIV [22]
Stat2 signal transducer and activator
of transcription 2
1.4 1.9 1.2 1.5 - - LAIV [21]
Irf7 interferon regulatory factor 7 1.7 2.9 1.7 1.1 - - LAIV [21]
Casp1 caspase 1 1.1 - 1.2 1.1 - -
Adaptive immune response
B cell related responses
Ighg Immunoglobulin heavy chain
(gamma polypeptide)
- - 1.5 1.6 - -
Ighg3 Immunoglobulin heavy constant
gamma 3
- - 1.3 1.2 - - TIV, correlated with decreased risk of
HIV-1 infection in the RV144 trial
ALVAC-HIV(vCP1521)
Ighm immunoglobulin heavy constant mu - - 1.1 - - - positively correllates with antibody
response to TIV
[21]
Igk immunoglobulin kappa chain
complex
- −1.0 - - - - positively correllates with antibody
response to TIV
[21]
T cell related responses
Gzmb granzyme B 3.7 4.7 4.1 4.2 2.4 - [20]
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Table 4 Comparison of early poxvirus-induced immune responses to selected innate molecular signatures of existing vaccine
vectors. Differences in Log2 Fold Changes (between each virus and the control) are depicted (Continued)
expressed by CD8+ T cells in
response to YF-17D
Ccr5 chemokine (C-C motif) receptor 5 1.1 1.5 1.3 1.3 - - expressed by CD8+ T cells in
esponse to YF-17D
[20]
Ccl2 (MCP1) chemokine (C-C motif) ligand 2 3.5 3.3 2.9 3.3 2.8 - predicted the magnitude of the CD8+
T cell response to Merck Ad5/HIV
[22]
HIV human immunodeficiency virus, LAIV live attenuated influenza vaccine, TIV trivalent influenza vaccine, YF-17D Yellow fever vaccine, Merck Ad5/HIV Merck’s
Adenovirus subtype 5-based HIV vaccine
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seasonal influenza vaccines [21] and the immunogenic but
inefficacious Merck Ad5/HIV vaccine [22]. Several of the
innate immune signatures observed in tested vaccines,
were common to one or more of the poxviruses investi-
gated here. The gene encoding monocyte chemotactic
protein 1 (MCP1) (Ccl2) was up-regulated by 5 out of the
6 poxviruses (MVA, LSDV,CNPV,FWPV and PEPV). This
gene was positively correlated with the CD8+ T cell re-
sponse to Merck Ad5/HIV vaccination [22]. Immuno-
globulin genes, Ighm (up-regulated by CNPV) and IgK
(down-regulated by LSDV) were positively correlated with
the antibody response to TIV influenza vaccination [21].
This suggests that the different poxviruses could be asso-
ciated with different levels of antibody induction during
the adaptive immune response. Based on our data we
speculate that LSDV may be more suitable for a T-cell
based vaccine and CNPV more suitable for the induction
of an antibody response. This reflects the published data
on LSDV [3] and CNPV [61].
Microarray analyses can provide important information
regarding the effect of different clinically relevant viruses
on host gene expression. One limitation of microarray
data analysis is that as of yet there are no standardised
methods of statistical analysis. It has been demonstrated
previously that fold change designations and p-value cut-
offs can significantly alter microarray interpretation [66].
Here we have chosen stringent fold change and p-value
cutoffs (log2FC ±1, adjusted p-value < 0.05) in line with
similar studies [11−14], in order to avoid false discovery
and inaccurate biological inferences. We concede that in
doing so, some smaller changes in gene expression may
have been overlooked. Further work should entail investi-
gating gene dysregulation at different times post infection.
Also, innate immune signatures should be directly corre-
lated with subsequent adaptive responses. Correlation of
gene expression data with biological or clinical findings
would be most informative.
Conclusions
The findings presented here indicate that six, genetically
diverse host-restricted poxviruses, CNPV, FWPV, FeP2,
PEPV, MVA and LSDV, produce qualitatively andquantitatively distinct host responses in an in vivo mouse
model. These results confirm that transcriptome analysis
in a mouse model can be used to determine if poxvirus




The growth of poxviruses in embyonated eggs and the
mouse experiments described below were approved by
the Animal Research Ethics Committee in the Faculty of
Health Sciences, University of Cape Town. The approval
numbers are 013/016 and 013/017 respectively.Viruses
MVA and wild-type CNPV were obtained from Prof. K.
Dumbell’s collection at the University of Cape Town and
were originally from Prof. A. Mayr (Germany). The fowl-
pox virus vaccine, DCEP 25 modified strain, was purchased
from Merial (Country) and LSDV vaccine, Herbivac®
(Ceva), was kindly donated by Deltamune (Pretoria, South
Africa). FeP2 was from a Feral Pigeon (Columba livia)
[26, 27] and PEPV from an African penguin (Spheniscus
demersus) [27, 29]. Virus isolates were grown and titrated
on the chorioallantoic membranes (CAMs) of embryo-
nated 10–11 day old (MVA, CNPV, FWPV) or 7 day old
(LSDV) Specific pathogen–free (SPF) White Leghorn
chicken eggs, which were obtained from Avifarms (Pty)
Ltd (Lyttelton, South Africa), using a method described
previously [26]. Titrations were performed on CAMs for
avipoxviruses and MVA and on Madin Darby bovine kid-
ney (MDBK) cells for LSDV.
Virus infection of mice
Seven week old naive female BALB/c mice were ran-
domly divided into groups of three and each mouse was
inoculated intravenously (i.v) with 105 pfu/100 ul pox-
virus, diluted in PBS or mock infected with PBS alone or
egg extract (100 μl). The egg extract was made from unin-
fected CAMs, following the same extraction and purifica-
tion procedure as the virus samples above. We compared
the gene expression profiles of the groups of mice that
Offerman et al. BMC Genomics  (2015) 16:510 Page 18 of 20were mock-infected with egg extract and PBS. No differ-
ence in gene expression was observed between the control
samples. For each different virus, three groups of three
mice each were inoculated. At 24 h post infection, the
mice were sacrificed by cervical dislocation without anaes-
thesia and the spleens were harvested and placed in RNA-
later (Qiagen, Venlo, Limburg, NL).RNA extraction
Mouse spleens were removed from RNAlater and the
three spleens in each group were pooled and homogenized
thoroughly using a TissueRuptor (Qiagen) in TRIzol® re-
agent (Life Technologies, Carlsbad, CA, USA). Total RNA
was isolated using TRIzol® Plus RNA Purification Kit (Life
Technologies, Carlsbad, CA, USA) with On-column PureLink®
DNase treatment according to manufacturer’s instructions.
RNA was resuspended in RNase free water and quality
checked using the Nanodrop ND1000 (Thermoscientific,
Waltham, MA, USA) and the Agilent Bioanalyzer Nano
Assay (Agilent, Santa Clara, CA, USA).Microarray and data analysis
mRNA hybridization was performed by IMGM La-
boratories GmbH (Martinsried, DE) with the Affyme-
trix GeneChip Mouse Gene 2.0 ST array (Affymetrix,
Santa Clara, CA, USA). Data analysis was performed
in R [67], using packages from the Bioconductor suite
(http://www.bioconductor.org), and CRAN (http://cran.r-
project.org). All R code is available in Additional file
1. Probe level data from. CEL files was normalised
using the Robust Multi-array Averaging (RMA) method
[68] obtained as part of the “affy” package [69] from Bio-
conductor, resulting in log2 transformed values. Boxplots,
scatterplots and histogram outputs of the normalised
data were obtained and checked for consistency (not
shown). Data was annotated using the Mouse Gene ST
2.0 annotation data package from Bioconductor. Non-
specific filtering was performed using the Genefilter pack-
age [70, 71]. This step included an intensity filter which
filtered the data set such that the intensity of each gene
should be > log2 (100) in at least 20 % of the samples. Sec-
ondly, a variance filter was applied such that the inter-
quartile range of log2-intensities should be at least 0.5.
Differential gene expression was determined using a
linear model approach using the R package, Limma
[34]. A heatmap was made using heatmap.2 from the
CRAN package gplots [72], and depicted the unsuper-
vised hierarchical clustering based on the genes with
p-value < 0.05 and log2FC above or below cutoff (±1).
Venn diagrams were made using Venny [73] available
at http://bioinfogp.cnb.csic.es/tools/venny/index.html.
Functional analysis was performed using Database for
Annotation, Visualization and Integrated Discovery(DAVID) v6.7 web-based tools (http://david.abcc.n-
cifcrf.gov/tools.jsp). Quantitative real time PCR was
done on selected mouse genes. GAPDH, HPRT and CD51
were selected as housekeeping genes; IRF7 and Zbp1 were
selected as genes which were moderately upregulated by
LSDV, MVA and avipoxviruses CNPV and FWPV; and
IGFbp3 was selected as a gene which was downregulated
by LSDV.
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